I. Executive Summary
A. Scope
B. Definition
C. Lung Cancer Epidemiology
D. Treatment Options Paradigm
E. Market Analysis and Forecasts
F. Therapeutic Class Assessment
G. Strategy Development

II. Objectives and Methodology
A. Report Objectives and Scope
B. Methodology
C. Data Collection
D. Strategic Recommendations

III. Lung Cancer Overview
A. Definition
B. Lung Physiology
C. Causes
D. Risk Factors
E. Symptoms of Lung Cancer
F. Diagnostic and Staging Techniques
G. Lung Cancer Epidemiology

IV. Lung Cancer Treatments
A. Treatment Options
B. Adjunctive Therapies

V. Lung Cancer Therapeutic Market
A. Worldwide Market
B. U.S. Market
C. Model Assumptions

VI. Current Lung Cancer Therapeutics
A. Market Overview
B. Mitotic Inhibitors
C. Alkylating Agents
D. Hormone Therapies
E. Cytotoxic Antibiotics

VII. Emerging Lung Cancer Therapeutics
A. Overview
B. Leading Products in Development
C. Compounds in Phase II
D. Compounds in Phase III or Later

VIII. Strategic Analysis
A. Overview
B. Identify Untapped Market Opportunities
C. Develop Top Business Scenarios
D. Implement Superior Sales and Pricing Strategies

Appendix A: Company Profiles
AstraZeneca PLC
Aventis S.A.
Bristol-Myers Squibb
British Biotech
Cell Genesys
Eli Lilly & Co.
Genentech, Inc.
GlaxoSmithKline
Isis Pharmaceuticals, Inc.
MedImmune, Inc.
Novartis AG
Pharmacia
Sanofi-Synthelabo, Inc.
Schering-Plough
Vertex Pharmaceuticals, Inc.
Appendix B: Definitions and Acronyms

For more information visit http://www.researchandmarkets.com/reports/c9449

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980